BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.

OBJECTIVE The object of this study was to test the hypothesis that BRAF is a low-risk susceptibility gene for low malignant potential (LMP) ovarian cancer. A recent study of the relationship between BRAF polymorphisms and malignant melanoma identified strong linkage disequilibrium across the BRAF gene with one of the three most common haplotypes (haplotype C) having a population attributable risk of approximately 1.6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential. METHODS We genotyped 383 cases of LMP ovarian cancer, including 234 of serous histology, and 987 controls for seven SNPs, representative of the most common BRAF gene haplotypes, using MALDI-TOF mass spectrometry. RESULTS Haplotype information was obtained for 369 LMP ovarian cancer cases and 983 healthy controls. None of the haplotypes were found to be associated with risk of LMP ovarian cancer (OR for haplotype C 0.81, 95% CI = 0.54-1.22), or with the risk of serous LMP ovarian cancer (OR for haplotype C 0.90, 95% CI = 0.56-1.45). CONCLUSION We found no evidence to suggest that BRAF is a low-risk LMP ovarian cancer susceptibility gene.

• Publication year

  2005

• Venue

  Gynecologic Oncology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2005.03.007PMID 15904951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAF polymorphisms and risk of melanocytic neoplasia.

  2005cited by this paper
• Journal of Carcinogenesis BioMed Central Review Estrogen, mitochondria, and growth of cancer and non-cancer cells

  2005cited by this paper
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• Ovarian Tumors of Low Malignant Potential

  2003cited by this paper
• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

  2003cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

  2003cited by this paper
• Estimation and Tests of Haplotype-Environment Interaction when Linkage Phase Is Ambiguous

  2003cited by this paper
• Borderline ovarian tumours: a review of the recent literature

  2003cited by this paper
• Blaustein’s Pathology of the Female Genital Tract

  2003cited by this paper
• Polymorphisms of the BRAF gene predispose males to malignant melanoma

  2003cited by this paper
• Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

  2002cited by this paper
• Missense mutations of the BRAF gene in human lung adenocarcinoma.

  2002cited by this paper
• Association testing by DNA pooling: An effective initial screen

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Score tests for association between traits and haplotypes when linkage phase is ambiguous.

  2002cited by this paper
• Molecular aspects of ovarian cancer.

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Ovarian tumors of low malignant potential

  2001cited by this paper
• Low‐dose oral contraceptives: Protective effect on ovarian cancer risk

  2001cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies.

  1998cited by this paper
• Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations

  1997cited by this paper
• Hereditary ovarian cancer: molecular genetics and clinical implications.

  1997cited by this paper
• Reproductive and other factors and risk of epithelial ovarian cancer: An australian case‐control study

  1995cited by this paper
• BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT

  1995cited by this paper
• Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.

  1991cited by this paper
• An efficient salt-chloroform extraction of DNA from blood and tissues.

  1989cited by this paper

• Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets.

  2025cites this paper
• Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets

  2023cites this paper
• The highs and lows of serous ovarian cancer

  2023cites this paper
• Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum

  2022cites this paper
• Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer

  2014cites this paper
• Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

  2013cites this paper
• Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk.

  2013cites this paper
• Genetic susceptibility to sporadic ovarian cancer: a systematic review.

  2011cites this paper
• Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma.

  2010cites this paper
• Malignant melanoma: genetics and therapeutics in the genomic era.

  2006cites this paper